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Abstract
Background: Apical membrane antigen 1 (AMA1) is a leading candidate vaccine antigen against blood-stage malaria,
although to date numerous clinical trials using mainly protein-in-adjuvant vaccines have shown limited success. Here we
describe the pre-clinical development and optimization of recombinant human and simian adenoviral (AdHu5 and ChAd63)
and orthopoxviral (MVA) vectors encoding transgene inserts for Plasmodium falciparum AMA1 (PfAMA1).
Methodology/Principal Findings: AdHu5-MVA prime-boost vaccination in mice and rabbits using these vectors encoding
the 3D7 allele of PfAMA1 induced cellular immune responses as well as high-titer antibodies that showed growth inhibitory
activity (GIA) against the homologous but not heterologous parasite strains. In an effort to overcome the issues of PfAMA1
antigenic polymorphism and pre-existing immunity to AdHu5, a simian adenoviral (ChAd63) vector and MVA encoding two
alleles of PfAMA1 were developed. This antigen, composed of the 3D7 and FVO alleles of PfAMA1 fused in tandem and with
expression driven by a single promoter, was optimized for antigen secretion and transmembrane expression. These bi-allelic
PfAMA1 vaccines, when administered to mice and rabbits, demonstrated comparable immunogenicity to the mono-allelic
vaccines and purified serum IgG now showed GIA against the two divergent strains of P. falciparum encoded in the vaccine.
CD8
+ and CD4
+ T cell responses against epitopes that were both common and unique to the two alleles of PfAMA1 were
also measured in mice.
Conclusions/Significance: Optimized transgene inserts encoding two divergent alleles of the same antigen can be
successfully inserted into adeno- and pox-viral vaccine vectors. Adenovirus-MVA immunization leads to the induction of T
cell responses common to both alleles, as well as functional antibody responses that are effective against both of the
encoded strains of P. falciparum in vitro. These data support the further clinical development of these vaccine candidates in
Phase I/IIa clinical trials.
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Introduction
It is estimated that in Africa alone there are 200 million cases
and 0.8 million deaths due to malaria every year [1]. Vaccines
remain one of the most effective public health interventions to
reduce morbidity and mortality. The worldwide eradication of
smallpox was due to vaccination and other infectious diseases (such
as poliomyelitis and rinderpest of cattle) are similarly on the brink
of eradication. In the case of malaria the development of a highly
effective vaccine remains a high priority. Vaccine-induced
immunity in an endemic area could help to significantly reduce
overall transmission by inducing herd immunity when combined
with pre-existing partially effective control interventions including
insecticide-treated bednets, artemisinin-based combination thera-
pies and indoor residual spraying [2]. Blood-stage malaria vaccines
aim to mimic immunity that is naturally acquired in malaria
endemic areas [3]. Individuals living in malaria endemic countries
develop immunity by repeated exposure to the parasite and a
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expressed on the blood-stage parasites or infected erythrocytes.
This immunity is mostly antibody mediated [4], although more
recently the importance of cellular immunity has begun to be
recognized in mice [5,6] and humans [7,8].
Blood-stage malaria subunit vaccine development has thus
mainly focused on antibody-inducing protein-in-adjuvant formu-
lations targeting well-studied merozoite antigens, including
merozoite surface proteins (MSPs) and antigens secreted from
apical organelles of the parasite during erythrocyte invasion, such
as apical membrane antigen 1 (AMA1). To date there have been
over 30 phase I/II clinical trials with these blood-stage antigens
reported [3], but the limited success of such candidates, combined
with reports of vaccine allele-specific efficacy in field trials [9] and
in in vitro assays of purified IgG growth inhibitory activity (GIA)
[10,11], indicates that blood-stage vaccines may need to include
multiple alleles of the same antigen to achieve significant efficacy
against the many strains of P. falciparum in the field.
PfAMA1 has been one of the leading blood-stage malaria
vaccine candidate antigens for a considerable time, and there have
been numerous pre-clinical and clinical AMA1 vaccine studies
(reviewed in Ref [12]). Field studies have primarily addressed the
importance of antibodies to PfAMA1 to clinical immunity,
showing that in naturally exposed individuals the prevalence of
PfAMA1-specific IgG increases with age and that this is associated
with reduced risk of clinical malaria [13,14,15]. However, the
PfAMA1 antigen is polymorphic, probably as a result of immune
selection operating on this important target of naturally occurring
immunity, and antibodies raised against individual naturally-
occurring alleles of this antigen inhibit growth of P. falciparum
strains in vitro in a strain-specific manner. A clinical trial of an
PfAMA1 3D7 allele protein vaccine (FMP2.1) showed that sera
from vaccinees, although capable of inhibiting growth of 3D7
strain P. falciparum parasites in vitro, afforded no inhibition of the
heterologous FVO strain [16].
Several different approaches have thus been developed to
address the issue of polymorphism [3]. The AMA1-C1 recombi-
nant protein vaccine in clinical development is composed of a
mixture of the 3D7 and FVO alleles [17] – two of the most
divergent in terms of polymorphism and which differ by 24 amino
acids out of 622 amino acids. It has been shown that vaccination
with multivalent or chimeric PfAMA1 vaccines increases the levels
of antibodies to common allele epitopes and/or broadens
inhibition of malaria strains [18,19,20]. Immunization with
diversity-covering (DiCo) PfAMA1 sequences, that on average
incorporate 97% of the amino acid variability observed in
PfAMA1, has also been shown to induce broader functional
immunity than immunization with mixtures of naturally-occurring
alleles [21].
Conversely, studies of T cell-mediated immunity against
PfAMA1 and/or blood-stage malaria infection in humans have
been more limited. In one epidemiological study, seven T cell
epitopes in PfAMA1 were reported, with some localized to
conserved areas of PfAMA1 – an important observation in terms
of vaccination strategy against this polymorphic antigen [22].
Individuals showing a proliferative response to one PfAMA1
peptide corresponding to aa 259–271 were found to be less likely
to be parasitemic on follow up [23]. Another study has shown
that repeated ultra-low dose exposure of malaria-naı ¨ve human
volunteers to blood-stage parasites and drug cure can induce
sterile protection against a blood-stage challenge. In this study
there was no detectable antibody response against the parasite. A
cell-mediated immune response was measured – mainly charac-
terized by a proliferative CD4
+ and CD8
+ T cell response and
Th1-type cytokine induction [7]. In another study, volunteers
were protected against malaria challenge with infected mosqui-
toes after sporozoite inoculation and chloroquine drug cure, and
parasite-specific pluripotent effector memory T cells before
challenge were found to be associated with protection [8]. In
rodent malaria models, there is strong evidence for the role of
CD4
+ T cells, interferon-gamma (IFN-c) and nitric oxide
contributing to the control of blood-stage parasitaemia [6,24],
including those cells against the AMA1 antigen [5]. Recently a
study in the P. chabaudi AS model showed that the failure to
maintain long-term protective responses was due to a gradual
decline in the parasite-specific memory CD4
+ T cell response,
despite persistent B cell memory and circulating antibodies [25].
This study provides an important insight into T and B cell
memory to malaria and encourages vaccination strategies that
induce memory T cells to ensure long-term efficacy. With
increasing evidence of the role for T cells, as well as antibodies, in
blood-stage malaria immunity, vaccine development strategies
should focus on vaccine platforms capable of generating both
humoral and cellular immunity [26]. This strategy could induce a
broader repertoire of immune responses to target such polymor-
phic malarial proteins.
Recently, replication-deficient recombinant viral vectored
vaccination regimens have been described that are capable of
inducing potent T cell and antibody responses against encoded
transgenes [27]. When targeting the blood-stage malaria antigen
MSP1, high level antibody-mediated protection could be
achieved in the P. yoelii mouse model of blood-stage malaria
infection by using a priming immunization with a recombinant
human adenovirus serotype 5 (AdHu5) vector followed by a
booster immunization with the poxvirus vector modified
vaccinia virus Ankara (MVA) [28]. The same regime induced
effector CD8
+ T cells that could reduce P. yoelii parasite burden
during the preceding liver-stage infection [29]. AdHu5 and
poxvirus vaccines encoding P. falciparum MSP1 and AMA1 have
also been reported [30,31,32]. The advantages of using
recombinant adenovirus vectors as vaccine carriers are numer-
o u sa n dc e r t a i ns e r o t y p e s ,s u c ha sA d H u 5 ,a r eh i g h l y
immunogenic [27]. However, the host generates an immune
response not only to the transgene but to the vector as well
[33,34]. AdHu5 vectors have been developed for vaccine
delivery for several diseases and tested in rodents, primates
and recently in humans as a vectored vaccine against HIV-1
[35] and malaria . Anti-AdHu5 immunity has been shown in
pre-clinical and clinical studies to hamper the immunogenicity
of recombinant AdHu5 vaccines [36,37,38]. Due to the need to
overcome this problem, simian adenovirus vaccine vectors, such
as chimpanzee ChAd63 (previously known as AdCh63), have
been developed for which there isl e s sp r e - e x i s t i n gi m m u n i t yi n
human populations [39,40]. We have recently reported that this
vector exhibits comparable immunogenicity to AdHu5 when
recombinant for the P. falciparum liver-stage antigen TRAP and
blood-stage antigen MSP1 [32,41,42]. Here we report the
iterative development of human and simian adeno- and pox-
viral vectored vaccines targeting two alleles of PfAMA1. These
vectors were tested in mice and rabbits to assess the cellular and
humoral immunogenicity of these vaccines in a prime-boost
vaccination regime. PfAMA1-specific antibody induction by
these viral vectors was optimized by using mammalian secretory
signal sequences and inclusion of the native transmembrane
domain for cell surface antigen localization. These data support
the rational design of vectored vaccine transgene inserts for
optimization of immune responses against multiple alleles of the
same antigen.
Viral Vectored Blood Stage Malaria Vaccine
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Antibody responses induced by AdHu5-MVA PfAMA1
(3D7) prime boost vaccination in mice and rabbits
PfAMA1-specific IgG antibody responses were measured by
ELISA in the serum of BALB/c mice and New Zealand white
rabbits after an AdHu5-MVA PfAMA1 (3D7) heterologous prime-
boost vaccination regimen using an eight week interval [28]. Both
vectors encoded a first generation PfAMA1 (3D7) vaccine
construct (aa 25–546) including the tPA leader sequence and with
mutations in potential N-linked glycosylation sites (as described in
Methods). In mice the kinetics of the total IgG response was
measured by ELISA against both the homologous 3D7 allele
(vaccine strain) (Figure 1A) and the heterologous FVO allele
(Figure 1B) to assess the induction of cross-reactive antibodies. All
mice seroconverted after the AdHu5-PfAMA1 (3D7) prime
(assessed at day 14) and these responses significantly increased
(P#0.05) by day 55 (pre-boost), in agreement with murine data for
similar AdHu5 vectors encoding the P. yoelii and P. falciparum
MSP1 antigens [28,32]. The MVA boost immunization on day 56
significantly increased (P#0.05) the PfAMA1-specific IgG anti-
body response as assessed on day 70 (two weeks post boost). Cross-
reactive antibodies were measured against the heterologous FVO
allele and there was a significant correlation (R
2=0.49, P=0.03)
between the antibodies to 3D7 and FVO PfAMA1 at the peak of
the response, day 70 (Figure 1C). The IgG isotypes (IgG1 and
IgG2a) were also measured in the sera and there was a balanced
Th1-type IgG2a and Th2-type IgG1 response in mice at the day
70 time-point (Figure 1D).
The kinetic of the IgGantibody response inrabbits after the same
immunization regime was different to that seen in mice. After
immunization with AdHu5-PfAMA1 (3D7) all the rabbits serocon-
verted, but the antibody response tended to be lower at day 55 post
prime in comparison to day 14 (P#0.05) (Figure 2A,B), unlike in
mice where there was a significant increase in the antibody response
overtime aftertheAdHu5-PfAMA1(3D7)prime.Administration of
the MVA boost on day 56 significantly increased the antibody
response by day 70. Measurement of cross-reactive antibodies
against FVO AMA1 showed there was a stronger correlation
between the 3D7 and FVO antibodies at day 70 in rabbits
(R
2=0.98, P#0.0001) than in mice (Figure 2C). The antibodies
induced by vaccination recognized native AMA1 protein as shown
by parasite immunofluorescence assay (IFA) (Figure 2D). IFA was
performed using slides of P. falciparum schizont infected red blood
cells (RBCs) which were incubated with day 70 sera from
immunized rabbits. The sera bound to the P. falciparum schizont
stages as shown by the punctate apical staining of merozoites that is
typical of that seen for AMA1 (Figure 2E).
Functional activity of antibodies generated in mice and
rabbits
The functional activity of antibodies induced by the AdHu5-
MVA PfAMA1 (3D7) vaccination regime was determined using a
standardized assay of growth inhibitory activity (GIA) [43], which
measures the growth inhibition of blood-stage P. falciparum
parasites by purified IgG. Mouse sera obtained at the day 70
time-point were pooled and the GIA was determined using a final
concentration of 5 mg/mL purified IgG. The samples showed a
GIA of 98% against 3D7 parasites (vaccine strain), but lower levels
against the heterologous FVO parasites (54%) (Figure 3A). Purified
control mouse IgG shows no significant biological activity against
either parasite strain in this assay [28]. The antibody response
(measured using a standardized ELISA [11]) against the 3D7 allele
was higher than FVO (Figure 3A).
Similar assays were performed for individual rabbit serum
samples taken two weeks after the final immunization, and GIA
was assessed against the homologous 3D7 and heterologous FCR3
strains using purified IgG at a final concentration of 6 mg/mL.
The AMA1 sequence of FCR3 differs from that of the FVO strain
by only a single amino acid [18]. In rabbits there was moderate
growth inhibition against the homologous 3D7 strain (medi-
an=44%, n=8) but little or no GIA against the heterologous
FCR3 strain (median=7%, n=8) (Figure 3B). This strain-specific
GIA of purified rabbit IgG has been reported in numerous other
studies using recombinant protein AMA1 vaccines [12,19]. There
was no correlation between 3D7 and FCR3% GIA (Figure 3C).
However, as seen in other studies [32] there was a positive
correlation between the 3D7 AMA1 ELISA titers and 3D7 GIA
(R
2=0.68, P#0.05) and also with FCR3 GIA (R
2=0.51, P#0.05)
(Figure 3D).
Generation of modified mono-allelic PfAMA1 vaccine
constructs
These preliminary data in mice and rabbits highlighted the need
to further optimize the PfAMA1 vaccine constructs in terms of
inducing antibodies capable of inhibiting the growth of divergent P.
falciparum strains. One recent study has demonstrated the ability of
co-immunization with two alleles of AMA1 to focus the induced
antibodies on conserved epitopes [18] and another demonstrated
enhanced antibody-inducing capability of an AdHu5 vaccine
expressing PfAMA1 (3D7) when localized to the cell surface in
comparison to intracellular expression [30]. The first generation
mono-allelic PfAMA1 vaccine described here utilized the signal
peptide from the human tissue plasminogen activator (tPA) as a
leader sequence in place of the native parasite N-terminal (N)
PfAMA1 signal sequence. However, the transmembrane domain
(TM) and the cytoplasmic tail (C) of PfAMA1 were not included in
this construct. As part of the process to develop a second generation
vaccine construct based on PfAMA1, the potential effects on
antibody immunogenicity of the addition of the native N and/or C
termini were tested. Three new recombinant AdHu5 vectors were
thus generated (second generation mono-allelic PfAMA1 (3D7)
vaccines) encoding the ectodomain of PfAMA1 (aa 25–546) with
either the native N terminal signal peptide or tPA leader and either
with or without the native C-terminal transmembrane and
cytoplasmic domains (aa 547–623) (Figure 4A), in order to
comparatively assess antibody immunogenicity.
Effect of the addition of the C-terminus on cellular
localization of PfAMA1
In order to confirm differences in the subcellular localization of the
PfAMA1 antigen following inclusion of the C-terminus in the vaccine
construct, an in vitro immunofluorescence assay was performed.
Transfection of HeLa cells with plasmid construct tPA-PfAMA1-C
containing the AMA1 C-terminus showed a cell surface localization
of PfAMA1 in both the permeabilized and non-permeabilized cells
(Figure 4D,E). In contrast, when using the construct tPA-PfAMA1
that expressed the construct without the C-terminal membrane
anchor, PfAMA1 expression was only detectablein the permeabilized
cells, presumably localized in the endoplasmic reticulum
(Figure 4B,C). These data confirmed that the addition of the C-
terminus led to the cell surface expression of PfAMA1.
Effect of replacing the native parasite signal peptide with
tPA as a leader sequence
The immunoflourescence assay does not quantify the effect of
replacing the N-terminal parasite signal sequence with tPA, so a
Viral Vectored Blood Stage Malaria Vaccine
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protein secreted/expressed from the two vectors: i) AdHu5-tPA-
PfAMA1 and ii) AdHu5-N-PfAMA1. In agreement with the
hypothesis that the mammalian leader sequence could enhance
transgene secretion and/or protein expression, there was consis-
tently more PfAMA1 protein in both the supernatant and the
lysate of the cells infected with the vector containing the tPA signal
peptide as compared to those infected with the vector containing
the native parasite AMA1 signal peptide (Figure 5A).
Comparative immunogenicity of modified PfAMA1
transgene inserts
Four groups of BALB/c mice were subsequently immunized with
the four different AdHu5 constructs: i) AdHu5-tPA-PfAMA1, ii)
AdHu5-tPA-PfAMA1-C, iii) AdHu5-N-PfAMA1 and iv) AdHu5-
N-PfAMA1-C.ThetotalIgGresponsetotheectodomainofPfAMA1
was measured by ELISA in the serum 12 days post vaccination
against recombinant PfAMA1 (3D7) protein (Figure 5B). Inclusion of
the human tPA leader sequence in the vaccine led to significantly
higher (P#0.05) antibody titers than when the native parasite N-
terminus was used, presumably due to increased efficiency of antigen
secretion and/or expression (Figure 5A). Interestingly, the antibody
responsewasmaintainedwhenthenativeC-terminuswasincludedin
the vaccine construct in conjunction with the tPA leader, and in fact
responses tended to be stronger when the C-terminus was used in
conjunction with the native N-terminal signal sequence. However,
the addition of the C-terminus did not further enhance the antibody
response when the tPA leader sequence was used in place of the
native N-terminus. These data indicate that although cell surface
localization may in some cases enhance the antibody immunogenicity
of AdHu5 recombinants, the efficiency of antigen secretion and/or
level of expression may be of greater importance.
Generation and immunogenicity of a bi-allelic PfAMA1
construct
A bi-allelic PfAMA1 vaccine construct was designed in an
attempt to address the issue of antigenic polymorphism in PfAMA1.
The 3D7 and FVO alleles utilized in other candidate protein
vaccines [17] were included and are two of the most divergent in
terms of amino acid (aa) polymorphism differing by 24 aa [20]. The
construct contained the ectodomains of the two alleles fused in
tandem and linked by a glycine-proline linker, as well as the tPA
leader sequence (at the N-terminus) and the TM region and C-
terminus of the FVO allele [44]. For pre-clinical studies this
construct was cloned into MVA (referred to as MVA-bi-allelic),
AdHu5 (AdHu5-bi-allelic) and the chimpanzee adenovirusChAd63
Figure 1. Murine antibody responses generated by AdHu5-MVA PfAMA1 (3D7) vaccination. 5–6 week old female BALB/c mice (n=7/
group) were immunized via the intradermal route with 5610
10 vp of AdHu5-PfAMA1 and boosted 8 weeks later with 1610
7 pfu MVA-PfAMA1. The
AMA1 specific antibody response against both homologous 3D7 (A) and heterologous FVO (B) PfAMA1 recombinant protein was measured in the
serum at day 14 (post prime), 55 (pre boost) and 70 (post boost). Data show the responses from individual mice and the lines represent the median.
The asterisk indicates a significant difference between the different time-points as analyzed by Wilcoxon signed rank test (* P #0.05). (C) The
correlation between the 3D7 and FVO antibodies at day 70 was analyzed using Pearson’s rank correlation (R
2=0.49, P #0.05). (D) IgG isotypes were
assessed at day 70 in the serum against recombinant FVO PfAMA1.
doi:10.1371/journal.pone.0020977.g001
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development of other P. falciparum candidate malaria vaccines
encoding the ME-TRAP [41] and MSP1 [32,42] antigens, and was
used in order to circumvent issues surrounding pre-existing anti-
vector immunity to AdHu5 in humans.
Mice were primed with either i) ChAd63-bi-allelic, ii) AdHu5-
bi-allelic or iii) the mono-allelic AdHu5-PfAMA1 (3D7) vectors.
Groups i) and ii) were boosted with MVA-bi-allelic and group iii)
was boosted with the mono-allelic MVA-PfAMA1 (3D7) vaccine.
Total IgG was measured in the serum on days 14, 55 and 70 by
ELISA against recombinant 3D7 and FVO PfAMA1. AMA1
specific IgG responses were detected in all the groups to both 3D7
(Figure 6A) and FVO (Figure 6B) recombinant proteins. Although
minor, but statistically significant differences were noted between
groups by one-way ANOVA analysis at day 14, by day 55 these
differences in IgG antibody responses had equalized between the
different groups, suggesting that after priming with ChAd63 rather
than AdHu5, the antibodies take slightly longer to reach maximal
levels. The MVA immunization significantly increased the
antibody response against both alleles in all the groups to similar
levels by day 70 (P#0.05). Thus, in agreement with data for the
MSP1 antigen [32], the ChAd63 and AdHu5 vectors expressing
the bi-allelic PfAMA1 construct primed similar IgG responses,
which remained equivalent after a heterologous MVA boost
Figure 2. P. falciparum AMA1 specific total IgG responses induced by immunization in rabbits. New Zealand rabbits (n=8) were
immunized via the intradermal route with 5610
10 vp of AdHu5-PfAMA1 (3D7) and boosted 8 weeks later with 5610
7 pfu of MVA-PfAMA1 (3D7). The
AMA1-specific antibody response against both homologous 3D7 (A) and heterologous FVO (B) PfAMA1 recombinant protein was measured in the
serum at day 14 (post prime), 55 (pre boost) and 70 (post boost). Data show the responses from individual rabbits and the lines represent the median.
The asterisk indicates a significant difference between the different time-points as analyzed by Wilcoxon signed rank test (* P #0.05, ** P #0.01). (C)
The correlation between the 3D7 and FVO antibodies at day 70 was analysed using Pearson’s rank correlation. There was a highly significant positive
correlation (R
2=0.96, P #0.0001). (D) IFA titers were measured using sera taken two weeks following the boost immunization. Individual IFA titers
against 3D7 and FCR3 P. falciparum strains are shown with the median response (FCR3 AMA1 differs from FVO AMA1 by only a single amino acid
substitution [18]). (E) When serum from immunized rabbits was used to label P. falciparum schizonts, typical AMA1-specific punctate apical staining of
merozoites was seen.
doi:10.1371/journal.pone.0020977.g002
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and bi-allelic AMA1 vaccine constructs was indistinguishable
based on the absolute IgG titers.
Comparison of antibody responses and serum GIA
generated in rabbits after vaccination with mono-allelic
or bi-allelic PfAMA1 vaccines
New Zealand white rabbits (n=4) were primed with 1)
ChAd63-bi-allelic, 2) AdHu5-bi-allelic or 3) the mono-allelic
AdHu5-PfAMA1 (3D7) vaccines. Groups 1) and 2) were boosted
with MVA-bi-allelic and group 3) was boosted with the mono-
allelic MVA-PfAMA1 (3D7) vaccine. Antibody levels were
measured two weeks after the final vaccination against 3D7
and FVO PfAMA1 (Figure 7A,B). As seen in mice, there was no
significant difference in the antibody response generated after
the three vaccination regimes either against 3D7 or FVO
PfAMA1. Cross-reactive antibodies were measured against the
FVO recombinant protein after immunization with the AdHu5-
MVA PfAMA1 (3D7) vaccination regime as seen previously
(Figure 2B). However, when antibody functionality was assessed
using the in vitro assay of GIA, the mono-allelic vaccine once
again induced strain-specific activity: 87.5% GIA against the
3D7 parasite but only 18.5% GIA against FVO (Figure 7C,D),
in agreement with the previous study (Figure 3B). However the
ChAd63-MVA bi-allelic and AdHu5_MVA bi-allelic vaccina-
tion regimes induced antibodies that showed comparable GIA
against both the 3D7 (58.5% and 79.5% respectively) and FVO
(54% and 57% respectively) parasites. GIA against 3D7 and
FVO parasite strains following bi-allelic immunization also
correlated significantly (Figure 7E). These data confirm that
even though mono- and bi-allelic PfAMA1 vaccine constructs
induce cross-reactive IgG that are indistinguishable by ELISA
assay, the IgG induced by the bi-allelic vaccines was capable of
reducing the growth of both parasite strains encoded by the
vaccine in vitro.
T cell immunogenicity and multi-functionality of the
mono-allelic and bi-allelic PfAMA1 vaccines in mice
T cell responses were also analyzed in BALB/c mice by ICS
following re-stimulation of splenocytes with one of four pools of
overlapping peptides (15 mers, overlapping by 10 aa) corre-
sponding to the 3D7 and FVO coding sequence in the bi-allelic
vaccine [44]. Pool 1 contained 64 peptides common to both
alleles of PfAMA1. Pools 2 and 3 (47 peptides in each) contained
allele-specific peptides unique to 3D7 and FVO respectively
(each peptide pair differ by 1 or 2 aa). Pool 4 had only 12
Figure 3. Growth inhibitory activity of sera from immunized mice and rabbits. 5–6 week old female BALB/c mice (n=7) were immunized as
in Figure 1. Sera were obtained two weeks post boost (day 70) by terminal bleed and the IgG was purified from the pooled sera. The GIA activity of
the serum was assessed by incubating the IgG at a final concentration of 5 mg/ml with P. falciparum cultures. The ELISA titers and the % growth
inhibition of the pooled serum are shown against both the homologous 3D7 and heterologous FVO strains of PfAMA1 (A). New Zealand white rabbits
(n=8) were immunized as in Figure 2. Two weeks after the final vaccination the sera were obtained. The effect of the purified IgG on parasite growth
from each individual rabbit was evaluated by incubating the IgG at a concentration of 6 mg/ml with mature P. falciparum schizonts. The % GIA values
for individual rabbits and the median are shown against both the 3D7 and FCR3 strains at 6 mg/ml IgG concentration (B). There was no correlation
between the 3D7 and FCR3 GIA (C). There was a significant positive correlation between the 3D7 ELISA titers and 3D7 GIA (R
2=0.68, *P #0.05) and
with FCR3 GIA (R
2=0.51, *P #0.05) using Pearson’s rank correlation (D).
doi:10.1371/journal.pone.0020977.g003
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Splenocytes were isolated from the mice described in Figure 6
on day 70 and re-stimulated with the four peptide pools or no
peptide control (Unstim) for 5 hours. After this, cells were
surface stained for CD4 and CD8 and then intracellularly
stained for IFN-c,T N F a and IL-2, before analysis by flow
cytometry for % of responding cells per total CD4
+ or CD8
+ T
cell subset (Figure 8A–H).
CD8
+ T cell responses were detected to the common, 3D7 and
FVO peptide pools. In all the three pools the ChAd63-MVA bi-
allelic PfAMA1 regime induced a significantly weaker CD8
+ T cell
response than the equivalent AdHu5-MVA regime (comparing
Figure 4. Schematic representation of the different PfAMA1 (3D7) constructs and effect of the addition of the C terminus on
cellular localization of PfAMA1. (A) The figure shows the different AdHu5 vaccine inserts generated to test the effect of replacing the human tPA
leader sequence with the native AMA1 N-terminal predicted signal peptide (aa 1–24) and also the effect of addition of the native transmembrane
domain and C-terminal cytoplasmic domain (aa 547–623). PfAMA1 in this figure represents the ectodomain of P. falciparum 3D7 AMA1 (aa 25–546).
Hela cells were grown on cover slips and transfected with the plasmid encoding tPA-PfAMA1 (B and C) or tPA-PfAMA1-C (D and E). After overnight
incubation polyclonal serum from immunized mice was used to detect the localization of PfAMA1. Alexa-conjugated anti-mouse antibody was used
as the secondary antibody and the DNA was stained with 49, 6-diamidino-2-phenylindole (DAPI). Cell surface localization of PfAMA1, notably on the
cell projections, was seen in the construct that has the C terminal domains in both the permeabilized (D) and non-permeabilized samples (E). There is
no cell surface associated PfAMA1 in the construct without the C terminal domains (B and C).
doi:10.1371/journal.pone.0020977.g004
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vectored PfAMA1 vaccine. (A) A549 cells were infected either with the same number of infectious units of AdHu5-tPA-PfAMA1 or AdHu5-N-
PfAMA1. The quantity of PfAMA1 protein was assessed in the supernatant and lysate by a PfAMA1 capture ELISA. The figure shows the OD405 values
for both the supernatant and the lysate for the two constructs. (B) Four groups of 5–6 week old female BALB/c mice were immunized with one of the
four constructs i) AdHu5-tPA-PfAMA1, ii) AdHu5-tPA-PfAMA1-C, iii) AdHu5-N-PfAMA1, or iv) AdHu5-N-PfAMA1-C at a dose of 1610
10 vp. The total IgG
response was measured by ELISA in the serum 12 days after immunization against P. falciparum 3D7 recombinant protein. The median and endpoint
titers (log 10) for individual mice are shown. The asterisk indicates a significant difference in endpoint titer between the groups by ANOVA (* P #0.05,
** P #0.01).
doi:10.1371/journal.pone.0020977.g005
Figure 6. Antibody responses in mice induced by the mono-allelic and bi-allelic PfAMA1 vaccine constructs. 6 week old female BALB/c
mice (n=6) were primed with 1610
9 vp of each of the adenovirus constructs i) ChAd63-biallelic, ii) AdHu5-biallelic and iii) AdHu5-PfAMA1 (3D7).
Groups i) and ii) were boosted at day 56 with 1610
7 pfu of MVA-biallelic and group iii) was boosted with the mono-allelic MVA-PfAMA1 (3D7). The
total IgG response was measured by ELISA in the serum at day 14, 55 and 70 against both the 3D7 (A) and FVO (B) alleles. The median and the range
of the endpoint titer (log 10) are shown in the figure. There were significant differences between the ELISA titres at day 14 by one-way ANOVA: 3D7
PfAMA1 ChAd63-biallelic versus AdHu5-monoallelic P ,0.001; FVO PfAMA1 ChAd63-biallelic versus AdHu5-biallelic P ,0.05. The MVA boost
significantly increased IgG titres against both alleles in all groups (* P ,0.05 by Wilcoxon signed rank test).
doi:10.1371/journal.pone.0020977.g006
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PfAMA1 vaccines. New Zealand rabbits (n=4) were primed with 1610
10 vp 1) ChAd63-biallelic, 2) AdHu5-biallelic or 3) AdHu5-PfAMA1 (3D7).
Groups 1) and 2) were boosted with 1610
7 pfu of the bi-allelic MVA construct and group 3) was boosted with the mono-allelic MVA-PfAMA1 (3D7).
The AMA1 specific antibody response against both homologous 3D7 (A) and FVO (B) PfAMA1 recombinant protein was measured in the serum two
weeks after the final immunization (day 70). There was no significant difference in the antibody responses between the groups against the 3D7 or
FVO alleles. The % GIA values for individual rabbits and the median are shown against both the 3D7 (C) and FVO (D) strains at 5 mg/ml IgG
concentration. There was a significant positive correlation between the 3D7 and FVO GIA (R
2=0.56, *P #0.05) (E).
doi:10.1371/journal.pone.0020977.g007
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and comparable CD8
+ T cell responses detected to the FVO pool
when mice were immunized with the AdHu5-MVA AMA1 (3D7)
mono-allelic regime (comparing groups B and C), indicating the
amino acid substitutions between the two allelic forms were either
not present in the epitope(s) recognized, or did not affect class I
MHC presentation or TCR recognition. The dominant CD8
+ T
cell response in BALB/c mice was to an epitope(s) in the 3D7 pool.
There was no response detected to the C-terminal region.
CD4
+ T cell responses were detected to all four peptide pools,
although the overall total magnitude of the response was lower
than the total CD8
+ T cell response. Consistent with the CD8
+ T
cell data, the ChAd63-MVA bi-allelic PfAMA1 regime induced an
overall weaker CD4
+ T cell response in comparison to the
equivalent AdHu5-MVA regime (comparing groups A and B,
P#0.05 for 3D7 and P#0.01 for FVO and C-term). The bi-allelic
AdHu5 vaccine construct tended to induce stronger responses
against the common, 3D7 and FVO pools in comparison to the
equivalent AdHu5 mono-allelic regime (comparing groups B and
C) but this did not reach statistical significance. Also as expected,
there was no response detected to the C-terminus when mice were
immunised with the mono-allelic 3D7 construct (which does not
contain the C-terminus), however the AdHu5 bi-allelic construct
which does contain this sequence induced detectable CD4
+ T cell
responses to this peptide pool.
Cross-reactive CD4
+ T cell responses were again detected to the
FVO pool of peptides when mice were immunized with the mono-
allelic 3D7 vaccine, possibly for similar reasons as for the CD8
+ T
cell responses. The induction of CD4
+ T cells against common
epitopes could be relevant to the issue of AMA1 polymorphism if
these epitopes are important for protection, as indicated by studies
of AMA1 in the P. chabaudi rodent malaria model [5,45]. The
multi-functionality of the CD4
+ T cell response to the common
pool was also assessed, given CD4
+ T cells producing IFN-c,
TNFa and IL-2 simultaneously have been shown to correlate with
protection against Leishmania major in mice [46]. All three
vaccination regimes induced multi-functional CD4
+ T cells, and
there were no significant differences in the quantity or quality of
multi-functional cells among the different vaccination regimes
tested (Figure 9).
Discussion
This paper describes the development, immunogenicity and in
vitro efficacy of a viral vectored vaccination strategy targeting one
of the leading blood-stage malaria vaccine candidate antigens
PfAMA1. This adenovirus-MVA prime-boost regime induces
antibody responses in mice and rabbits, and these antibodies
inhibit growth of P. falciparum parasite strains in vitro according to
the alleles of PfAMA1 encoded by the recombinant viruses. The
same vaccination strategy encoding another blood-stage vaccine
candidate antigen (P. falciparum MSP1) has been shown to be
similarly effective [32]. In addition to antibodies, this regimen also
induces substantial antigen-specific CD8
+ and CD4
+ T cells in
mice. The viral vectored vaccine platform is now offering a safe
and reliably immunogenic alternative to recombinant protein-in-
adjuvant vaccines not only for malaria vaccine development [47],
but also for a wider range of difficult infectious diseases [27].
The first generation AdHu5-MVA mono-allelic AMA1 (3D7)
vaccines induced cross-reactive antibodies to the heterologous
FVO allele of AMA1 both in mice and rabbits as measured by
ELISA, however there was a better correlation in rabbits than in
mice between the 3D7 and FVO antibodies at the peak day 70
time-point. This has been seen before with a P. falciparum MSP1
based vaccine [32], suggesting there are differences in antibody
cross-reactivity and B cell epitopes recognized in different
mammalian species. These observations may be reflected in
differing concentrations of inter-species IgG required to elicit
equivalent functional activity in vitro – an observation now reported
for both blood-stage antigens MSP1 and AMA1 [19], and also the
transmission-blocking vaccine candidate antigen Pfs25 [48]. In
another study, IgG isolated from rabbits immunized with a
reduced AMA1 ectodomain were reported to not have any growth
inhibitory activity in vitro [49]. Importantly, the first generation
vaccines described here induced antibodies capable of recognizing
antigen in its native conformation in schizont-infected erythro-
cytes, an observation also reflected in the measurement of
functional GIA. In this study in mice there was 94% GIA against
the homologous 3D7 strain but only 54% against the heterologous
strain. Similarly in rabbits there was a median GIA of 44% against
3D7 but there was no cross-reactive GIA against the FVO or
FCR3 strains of P. falciparum in vitro afforded by purified IgG after
immunization with the mono-allelic PfAMA1 (3D7) vaccine.
Purified IgG from immunized mice thus shows better cross-strain
in vitro inhibition than IgG from rabbits, though conversely in
rabbits the correlation between 3D7 and FVO antibodies as
measured by ELISA is stronger. These data are not in agreement
with a report where the pattern of strain specificity was found to be
similar in mice and rabbits [19], but do agree with other AMA1
vaccine studies, whereby the cross-reactivity of antibodies seen by
ELISA was not reflected in functional GIA assays [17,49,50,51].
This study also confirms observations made by others that
antibodies measured by ELISA against heterologous alleles of
AMA1 do not have equal effect on parasite growth in vitro [49].
However, reports describe a clear sigmoidal relationship between
in vitro GIA and ELISA titer for homologous alleles of both AMA1
and MSP1 [11].
The assay of GIA remains the gold-standard for pre-clinical
screening of blood-stage malaria candidate vaccines. However, a
recent Phase IIa clinical trial with a recombinant AMA1 protein
vaccine failed to induce significant clinical efficacy or any delay in
time to clinical diagnosis even though IgG purified from the
vaccinated serum showed very high levels of GIA in vitro [52].
More recent epidemiological studies in the field have shown a
weak contribution of GIA towards reduced malaria risk [53], and
other studies have shown conflicting results [54,55]. An alternative
in vitro assay, measuring antibody-dependent respiratory burst
(ADRB) activity from neutrophils has recently been associated
with clinical protection in a study from Senegal [56], and may
provide a complementary assay for screening vaccine-induced IgG
functional activity.
In the second generation 3D7 PfAMA1 vaccines, the substitu-
tion of the native parasite AMA1 leader sequence with the
mammalian tPA leader was shown to lead to significantly
improved antibody responses in mice immunized with the
recombinant AdHu5 vector. The tPA signal sequence is a specific
targeting signal that targets the expressed antigen to the
endoplasmic reticulum (ER) [57] and influenza virus nucleopro-
tein when fused to tPA was shown to be expressed at higher levels
and was found to be in a partially secreted form in vitro [58]. When
fused to the tPA signal sequence, viral envelope protein E of
Japanese encephalitis virus was expressed at higher levels in
transfected cells than the wild-type construct and was mainly
localized in the cytosolic and membrane fraction. These tPA
fusion constructs elicited stronger humoral and cellular response
and better protection against viral challenge in animals [59]. The
increased antibody response seen here with this construct can thus
be due to better secretion or enhanced PfAMA1 expression due to
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PLoS ONE | www.plosone.org 10 June 2011 | Volume 6 | Issue 6 | e20977Figure 8. T cell responses induced in mice by vaccination with the mono-allelic and bi-allelic constructs. 5–6 week old female BALB/c
mice (n=6) were immunized as in Figure 6. Splenocytes were isolated two weeks after the final immunization (day 70) and stimulated with four
peptide pools (Common, 3D7, FVO and C-terminus) or no peptide (Unstim) for 5 hours. After this time the cells were surface stained for CD4 and CD8
and then intracellularly stained for IFN-c, TNFa and IL-2 and analysed by flow cytometry for % of responding cells per total CD4
+ or CD8
+ T cell subset.
% CD4
+ and CD8
+ T cells positive for IFN-c, TNF-a or IL-2 following the different vaccination regime is shown (8A-H). Individual data points and the
median are shown. The asterisk indicates a significant difference between the groups by ANOVA (* P #0.05, ** P #0.01).
doi:10.1371/journal.pone.0020977.g008
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capture ELISA assay. Either or both of these mechanisms could
account for the increased immunogenicity of the AMA1 vaccine
constructs in which the native signal peptide was replaced with
tPA. The construct that included the PfAMA1 C-terminal
domains (transmembrane and cytoplasmic) allowed cell surface
localization, but this was found to improve humoral immunoge-
nicity only in combination with the native signal peptide, and did
not significantly further improve the tPA containing construct. In
agreement with these data, it has been previously reported that
antigens expressed at the cell surface were better than intracellular
antigens at inducing antibody responses [30].
Polymorphism in AMA1 has been one of the main hurdles in
vaccine development targeting this antigen. AMA1 polymor-
phisms are under balancing selection, especially within domains I
and II that are the most polymorphic. It has been speculated that
these polymorphisms are maintained due to selective pressure by
the host immune system [60,61,62,63]. In an attempt to overcome
the allele-specific functionality of the IgG induced by the first
generation vaccines, bi-allelic PfAMA1 vectored vaccines were
developed that also incorporated the tPA leader and C-terminal
region of one allele of PfAMA1. Multi-allele AMA1 protein
vaccines have been developed by several groups. Approaches have
included a 50:50 mixture of recombinant 3D7 and FVO AMA1
antigen formulated in Alhydrogel 6 CpG adjuvant (AMA1-C1)
[64], as well as a diversity covering (DiCo) approach that covers
97% of the amino acid variability in PfAMA1 [21]. These multi-
allelic vaccines show better cross-reactivity in terms of GIA than
mono-allelic vaccines, and interestingly in one study have been
shown to focus antibody responses on conserved B cell epitopes
[18]. Data on human antibody responses to PfAMA1 show that
affinity purified antibodies from individuals living in malaria
endemic areas can inhibit P. falciparum growth in vitro [49], and
Cortes et al. have also examined the allele specificities of plasma
samples of adults from Papua New Guinea and found that
antibodies against conserved regions of the molecule were much
more common than allele-specific antibodies [14]. In this study in
mice, the AdHu5-MVA and ChAd63-MVA bi-allelic PfAMA1
vaccination regimes induced antibodies that bound both the 3D7
and FVO recombinant proteins by ELISA. Although slightly
weaker responses were observed at the day 14 time-point when
using ChAd63, these responses equalized by day 55 and were
Figure 9. Multi-functionality of CD4
+ T cell response induced by vaccination. The multi-functional composition of the CD4
+ T cell response
(measured in Figure 8) is shown. The pie charts summarize the fractions of AMA1-specific CD4
+ cells that are positive for a given number of functions
(IFN-c, TNF-a and IL-2). Individual data points and median percentage of the parent CD4
+ T cell response (open bars) are shown for each of the
functional populations indicated on the x-axis.
doi:10.1371/journal.pone.0020977.g009
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agreement with those for similar vectors encoding P. falciparum
MSP1 [32], and confirm that, at least in mice, ChAd63 can be
used to replace AdHu5 in this adenovirus-MVA prime-boost
vaccination regime without compromising the humoral immuno-
genicity of the transgene product. Since seropositivity against
AdHu5 is too prevalent to permit its widespread deployment in
humans, these data support its replacement with ChAd63 as a
vaccine vector.
Notably in these mice, overall IgG titers were comparable
whether using mono- or bi-allelic vaccines. Rabbits were thus
immunized with both the vaccine constructs in order to purify IgG
and assay for functional GIA against both the 3D7 and FVO
strains of PfAMA1 to provide a comparison of the efficacy of the
two vaccine constructs. Encouragingly the bi-allelic vaccines
induced antibodies in rabbits that showed significant GIA against
both the 3D7 and FVO strains unlike the mono-allelic vaccine.
These data have also been confirmed in a recent macaque study,
showing the ChAd63-MVA bi-allelic PfAMA1 regime induces
significant GIA against both the 3D7 and FCR3 strains [44].
However, it has also been reported that the allele specificity of
antibodies to PfAMA1 depends on the species immunized [19].
Interestingly, unlike for mice and rabbits discussed earlier,
immunization of rhesus monkeys with recombinant PfAMA1
showed a completely different strain specificity pattern in terms of
GIA. Even when monkeys were immunized with single-allele
PfAMA1 vaccines, the elicited antibodies could bind indistin-
guishably to both homologous and heterologous PfAMA1 proteins
on ELISA plates, and the antibodies showed cross-reactive
biological activities, as judged by GIA and antigen reversal GIA
assays [19]. Thus despite the evidence in our recent macaque
study, these rabbit data confirm the value, at least in this species, of
developing multi-allelic PfAMA1 vectored vaccines.
Splenic T cell responses in mice to both common and unique
pools of peptides were also measured here by flow cytometry, and
CD4
+ T cells to the common pool displayed a multi-functional
phenotype in terms of IFN-c TNFa and IL-2 production. This is
encouraging because if CD4
+ or CD8
+ T cells recognizing
common epitopes in humans are important for protection, then
they could help to confer efficacy against heterologous strains. In
agreement with this hypothesis, there have been suggestions based
on analysis of sequence polymorphism frequencies that the
selection pressure on AMA1 domain III is mediated by T-cell
immunity [13]. In another recent study, pluripotent effector
memory T cells against infected erythrocytes have been associated
with protection in humans after a vaccination with sporozoites and
treatment with choloroquine [8]. In the P. chabaudi model, in
agreement with another study [5], we have shown a protective role
of vaccine induced CD4
+ T cells against blood-stage infection by in
vivo depletion and adoptive transfer studies [Biswas et al.,
submitted]. We have also shown that MSP1-specific CD8
+ T
cells can reduce the liver-stage parasite burden in the P. yoelii
model [29], and a similar mechanism may be relevant to AMA1 –
an antigen also expressed by sporozoites [65] and most likely also
late in the liver-stage of infection.
Although we have shown here that the ChAd63 vector induced
comparable antibody immunogenicity to AdHu5, there were some
differences in relation to other studies using this vector for the pre-
erythrocytic ME-TRAP antigen [41] and the blood-stage antigen
MSP1 in mice [32]. Unlike for ME-TRAP and MSP1, the AMA1-
specific CD4
+ and CD8
+ T cell responses were lower following
ChAd63_MVA immunization in comparison to those induced by
AdHu5_MVA expressing the same vaccine construct. It is possible
these differences may be antigen- and/or insert-specific and, in
agreement with these murine data, weak AMA1-specific T cell
responses were also induced in rhesus macaques following
immunization with this vector, although they boosted to high
levels following MVA [44].
Here we have described the rational design of bi-allelic PfAMA1
vectored vaccines that induce functional antibodies against two
parasite strains. The addition of the mammalian tPA leader
sequence to the adenoviral vectored vaccine insert significantly
increases the antibody response, and this adenovirus-MVA prime-
boost vaccination regime also induces T cell responses to
conserved epitopes. The responses to conserved B and T cell
epitopes following bi-allelic AMA1 immunization may improve
the strain-transcending efficacy of PfAMA1 vaccines in humans.
Overall, these data support the rational design of vectored vaccine
transgene inserts for optimization of immune responses against
multiple alleles of the same antigen, as well as the continued
development of these vectors towards phase I/IIa clinical testing.
Materials and Methods
Generation of viral vectors expressing AMA1
The first generation mono-allelic AMA1 construct encoded the
ectodomain of P. falciparum 3D7 AMA1 (amino acid 25–546), and
included a number of amino acid substitutions to remove
potential sites of N-linked glycosylation and was codon optimized
for expression in humans (GeneArt, Regensburg, Germany), as
described elsewhere [17]. The native predicted N-terminal signal
sequence (N), transmembrane domain (TM) and the C-terminal
cytoplasmic domain (C) were not included in the construct. The
human tissue plasminogen activator (tPA) leader sequence
replaced the native AMA1 signal sequence as previously
described [28]. This construct was used to make recombinant
E1 and E3 deleted human adenovirus serotype 5 (AdHu5) and
the attenuated orthopoxvirus modified vaccinia virus Ankara
(MVA) expressing AMA1. The methods used for the generation
of the vectors have been previously described [32,42]. The
second generation mono-allelic AMA1 vaccines are described in
Figure 4A. A final construct was designed to contain a fusion of
two divergent alleles of AMA1 (3D7 and FVO) linked by a
Glycine-Proline (GGGPGGG) linker. It also had the human tPA
leader sequence and the TM and C terminus from the FVO
strain and was human codon optimized. This construct (3483 bp
in length) is described elsewhere [44] and was cloned into AdHu5
and MVA as before, as well as E1/E3 deleted chimpanzee
adenovirus 63 (ChAd63, previously known as AdCh63) as
described [32].
Animals and Immunizations
Female BALB/c (H-2
d) mice 5–6 weeks old (John Radcliffe
Hospital, Oxford, UK or Harlan, UK) were used in all
experiments. All procedures were performed according to the
terms of the UK Animals (Scientific Procedures) Act Project
License (PPL 30/2414) and Personal License (PIL 30/7792) and
were approved by the University of Oxford Animal Care and
Ethical Review Committee. The vaccines were diluted in
endotoxin-free Dulbecco’s PBS prior to immunization. Vaccines
were administered intradermally (i.d.) bilaterally into the ears in a
total volume of 50 ml for both recombinant adenovirus and MVA.
The doses of recombinant adenovirus vaccines used were 5610
10
viral particles (vp), 1610
10 vp or 1610
9 vp and the dose of
recombinant MVA vaccine used was always 1610
7 plaque
forming units (pfu) [29,44]. The interval between the prime
immunization with AdHu5-AMA1 or ChAd63-AMA1 and
boosting with MVA-AMA1 was 8 weeks for all the regimens.
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The vaccines were shipped from Oxford and the immunization of
rabbits and collection of sera was performed by Biogenes GmbH,
Berlin, Germany (for the mono-allelic AMA1 rabbit experiment)
or Agro-bio, France (for comparison of mono-allelic and bi-allelic
vaccines). Rabbits were immunized i.d. or intramuscularly (i.m.)
with 5610
10 vp of AdHu5 or ChAd63 expressing AMA1 and
5610
8 pfu of MVA AMA1.
Total IgG ELISA
The antibodies induced by vaccination were measured by
ELISA as previously described [28]. Briefly, recombinant
PfAMA1 protein was adsorbed to 96 well Nunc-Immuno
Maxisorp plates at a concentration of 2 mg/ml in PBS. 3D7
AMA1 was a kind gift from Dr Chetan Chitnis (ICGEB, New
Delhi, India) and FVO AMA1 was a kind gift from Dr Mike
Blackman (NIMR, London, UK). After blocking, the serum was
incubated for 2 h and the bound antibodies were detected using
alkaline phosphatase-conjugated goat anti-mouse (Sigma A3562)
or anti-rabbit (Sigma A8025) IgG (whole molecule) diluted 1:5000.
Serum antibody endpoint titers were taken as the x-axis intercept
of the dilution curve at an absorbance value 36 standard
deviations greater than the OD405 for naive mouse serum (typical
cut-off OD405 for positive sera=0.15). Naı ¨ve mice sera were
pooled and used as controls for all the ELISAs and they were
negative against both recombinant 3D7 and FVO PfAMA1
protein. Standardized ELISAs for PfAMA1 were performed as
described elsewhere [11].
Isotype ELISA
Mouse IgG isotype ELISA assays were performed exactly as for
total IgG, except antibodies were detected by incubation for 1 h at
room temperature (RT) with biotinylated rat anti-mouse IgG1 or
IgG2a mAbs diluted to 1 mg/ml in Phosphate Buffered Saline
+0.05% Tween. Plates were washed 66 in PBS/T and then
incubated for 30 min at RT with ExtrAvidin conjugated to
alkaline phosphatase (Sigma) diluted 1:5000 in PBS/T. After the
incubation the plates were developed as for total IgG.
In vitro Growth Inhibitory Activity (GIA) Assay
Sera from immunized animals were used to test their ability to
inhibit parasite growth. The purified IgG was mixed with P.
falciparum infected human red blood cells and the growth inhibition
activity of the serum was determined by measuring parasite lactate
dehydrogenase (pLDH) release after a 40–48 hour incubation
period. Purified IgG was tested against 3D7, FVO, or FCR3
strains of P. falciparum at 5 or 10 mg/ml. The mouse and rabbit
GIA assays were performed using a standardized method [10] at
the GIA Reference Centre (Laboratory of Malaria and Vector
Research, NIH) against both 3D7 and FVO strains of P. falciparum
parasites. The rabbit GIA assay (Figure 3B) against the 3D7 and
FCR3 strains of P. falciparum was undertaken at the Biomedical
Primate Research Centre, The Netherlands against the 3D7 and
FCR3 parasite strains following a similar protocol [21].
Multiparameter Flow Cytometry
Cytokine secretion by peripheral blood mononuclear cells
(PBMCs) and splenocytes were assayed by intracellular cytokine
staining (ICS). PBMCs and Splenocytes were prepared as
previously described and added to a 96-well U-bottom plate.
50 ml of Brefeldin A (GolgiPlug) at 1 mg/ml and 50 ml of peptide
pools [44] diluted in complete medium at a final concentration of
1 mg/ml were added to the test wells. In the control wells
GolgiPlug and medium alone were added. Cells were incubated at
37uC5 %C O 2 for 5 h. After incubation the cells were left at 4uC
overnight. The next day cells were surface stained for 30 min at
4uC with PerCP-Cy5.5-conjugated anti-mouse CD8a (clone 53-
6.7) and Pacific blue (PB)-labelled anti-mouse CD4 (clone LT34)
diluted in PBS with 0.1% BSA at a dilution individually assessed
by titration for each antibody. Cells were then permeabilized in
100 ml1 6Cytofix/Cytoperm solution for 20 min at 4uC and then
intracellularly stained for 30 min at 4uC with APC-conjugated
anti-mouse IFN-c (clone XMG1.2), FITC-conjugated anti-mouse
TNFa (clone 145-2C11) and PE-conjugated anti-mouse IL-2
(clone JES6-5H4). After staining, cells were resuspended in 200 ml
PBS containing 1% formalin. Stained cells were acquired using a
LSRII flow cytometer (BD Biosciences) and data analyzed using
FlowJo v9 (Tree Star Inc, USA), Pestle and SPICE (Mario
Roederer, VRC, NIAID, NIH) software. Background responses in
unstimulated cells were subtracted from the stimulated responses
prior to analysis.
Immunofluorescence Assay (IFA)
Hela cells (obtained from European Collection of Cell Cultures,
UK) were grown on 22 mm coverslips in 6-well plates to about
50% confluency. 20 ml Lipofectamine 2 K and 500 ml Optimem
(Invitrogen) (for each well) were mixed and incubated for 5 min at
RT. 4 mg plasmid DNA of the individual constructs corresponding
to the transgenic insert in recombinant adenoviruses and
comprising a human CMV promoter and bovine growth hormone
polyadenylation signal were gently mixed with 500 ml of Optimem
(per well). The DNA-Optimem and the Lipofectamine-Optimem
solutions were combined and incubated for 20 min at RT. These
were then used to transfect the cells grown on the coverslips by
adding 1 ml of the solution to each well. These were incubated for
3–4 h at 37uC and 5% CO2 in a humidified incubator and then
1 ml of Optimem was added to each well and left overnight. The
plates were kept on ice and the cells were gently washed twice with
ice-cold PBS. The cells were then fixed with 4% paraformalde-
hyde in PBS for 10 min on ice and then 20 min at RT. The cells
were then washed with PBS three times over 10 min and
quenched with 50 mM ammonium chloride for 5 min. After this
the cells were permeabilized (if required) with 0.2% Tween-100 in
PBS for 5 min and washed 3 times with PBS. If the cells were not
permeabilized only the cell surface protein is accessible for
immunolabelling. The cells were then blocked with 0.5% BSA
in PBS for 30 min and then incubated with polyclonal mouse
serum from mouse immunized with AdHu5-PfAMA1 and MVA-
PfAMA1 diluted 1:100 in PBS. After 30 min Alexa 548-
conjugated anti-mouse IgG (1:200 dilution) was added (Invitrogen,
UK) and incubated for another 30 min. After the incubation the
cells were washed with PBS and the cover slip was mounted using
30 ml Mowiol-DAPI (49,69-diamino2-phenylindole, 500 ng/ml).
Slides were imaged using a Leica DMI3000B epifluorescence
microscope and a Qicam (Qimaging).
The parasite immunofluorescence assay was performed accord-
ing to a published protocol [66]. Cold methanol-fixed smears
prepared from a synchronized culture of P. falciparum with fully
mature schizonts were used for the assay. The slides were fixed
with acetone and incubated for 30 min with a serial dilution of the
post immunization serum and control serum in PBS containing
1% BSA and 0.01% sodium azide. After incubation these were
washed and incubated with a 1:80 dilution of FITC-conjugated
goat anti-rabbit IgG (Dako, UK) for 30 min. The slides were
immersed in a solution of 0.1% Evans blue and 0.001% DAPI and
mounted on coverslips and examined microscopically as above.
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Adenovirus infectious units (i.u.) were titered by immunostain-
ing, carried out by infection of 293 cells with serial dilutions of
virus. Forty-eight hours post-infection, cells were stained with anti-
hexon antibody (Cambridge Bioscience, UK) and detected with
HRP-conjugated secondary antibody (Cambridge Bioscience, UK)
and ImmPact DAB reagent (Vector Labs, UK). 1610
6 A549 cells
were infected with either 1610
7 i.u. of AdHu5-tPA-PfAMA1 or
AdHu5-N-PfAMA1. Two days later both the supernatant and the
lysate were harvested separately. Briefly, rat anti-PfAMA1
monoclonal antibody 4G2 was adsorbed to 96 well Nunc-Immuno
Maxisorp plates at a concentration of 100 mg/well in PBS. After
blocking with 10% skimmed milk in PBS with 0.05% Tween-20
(PBS/T), the supernatant and lysate were diluted 1:50 and 1:500
in PBS/T and incubated for 2 h, before addition of rabbit anti-
PfAMA1 polyclonal serum (diluted 1:1000 in PBS/T) and
incubation for a further 2 h. The bound antibodies were detected
using alkaline phosphatase-conjugated goat anti-rabbit (Sigma
A8025) IgG (whole molecule) diluted 1:5000. The OD405 values
were measured.
Statistical analysis
Data were analyzed for statistical significance using GraphPad
Prism v5 for windows (GraphPad Software, San Diego, CA). The
normality of the data set was determined using the Kolmogorov-
Smirnov one-sample test. For non-parametric data a Mann-
Whitney U test was used to compare two groups and a Kruskal-
Wallis test was used to compare more than two groups. Parametric
data were compared either using t-test (for comparing two groups)
or one-way ANOVA (for more than two groups). A post-hoc
Dunnet’s correction was used to compare groups to one control
group, whilst a Bonferroni correction was used when all the groups
were compared to each other. ELISA titers were logarithmically
(log10) transformed in order to normalize the data and enable a
more stringent parametric analysis. Wilcoxon signed rank test
was performed to compare mean responses between paired data
across two observations. Correlations were tested using Pearson
rank correlation for parametric data (log-transformed data) or
Spearman’s rank correlation for non-parametric data. P # 0.05
was considered significant in all cases (*P# 0.05, ** P # 0.01 and
***P # 0.001).
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